Your browser doesn't support javascript.
Decline In New Starts Of Psychotropic Medications During The COVID-19 Pandemic.
Nason, Ian; Stein, Dorit T; Frank, Richard G; Stein, Murray B.
  • Nason I; Ian Nason (nason@g.harvard.edu) is a PhD candidate in the Department of Health Care Policy, Harvard Medical School, in Boston, Massachusetts.
  • Stein DT; Dorit T. Stein is an incoming PhD student in the Department of Global Health and Population, Harvard T. H. Chan School of Public Health,in Boston, Massachusetts.
  • Frank RG; Richard G. Frank is the Margaret T. Morris Professor of Health Economics in the Department of Health Care Policy, Harvard Medical School.
  • Stein MB; Murray B. Stein is Distinguished Professor of Psychiatry and Public Health, University of California San Diego, in La Jolla, California.
Health Aff (Millwood) ; 40(6): 904-909, 2021 06.
Article in English | MEDLINE | ID: covidwho-1280643
ABSTRACT
COVID-19 interrupted delivery of mental health care in the US. During the initial course of the COVID-19 pandemic new starts of antidepressants declined by 7.5 percent, anxiolytics by 5.6 percent, and antipsychotics by 2.6 percent compared with expected levels. Our findings suggest that there is large unmet need for mental health treatment in the US due to COVID-19.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antipsychotic Agents / COVID-19 / Mental Disorders Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Health Aff (Millwood) Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antipsychotic Agents / COVID-19 / Mental Disorders Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Health Aff (Millwood) Year: 2021 Document Type: Article